Zhuang H, Alavi A 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002, 32:47-59.
Basu S, Zhuang H, Torigian DA, et al. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 2009, 39:124-145.
Biswal S Molecular imaging of musculoskeletal diseases. Semin Musculoskelet Radiol 2003, 7:317-350.
O'Connor MK, Brown ML, Hung JC, et al. The art of bone scintigraphy. Technical aspects. J Nucl Med 1991, 32:2332-2341.
Spencer DG, Adams FG, Horton PW, et al. Scintiscanning in ankylosing spondylitis: a clinical, radiological and quantitative radioisotopic study. J Rheumatol 1979, 6:426-431.
Song IH, Carrasco-Fernandez J, Rudwaleit M, et al. The diagnostic value of scintigraphy in assessing sacro-iliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 2008, 67:1535-1540.
Rosenthall L Nuclear medicine techniques in arthritis. Rheum Dis Clin North Am 1991, 17:585-597.
Helfgott S, Rosenthall L, Esdaile J, et al. Generalized skeletal response to 99mtechnetium methylene diphosphonate in rheumatoid arthritis. J Rheumatol 1982, 9:939-941.
Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by autoradiography. J Nucl Med 1992, 33:1972-1980.
Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995, 36:1301-1306.
Hustinx R, Malaise MG PET imaging of arthritis. PET Clin North Am 2006, 1:131-139.
Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998, 39:1302-1305.
Bombardieri E, Aktolun C, Baum RP, et al. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003, 30:BP115-BP124.
Bolus NE, George R, Washington J, et al. PET/MRI: the blended-modality choice of the future?. J Nucl Med Technol 2009, 37:63-71.
Webb M, Chambers A, Al-Nahhas A, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 2004, 31:627-634.
Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006, 55:131-137.
Walter MA [18F]fluorodeoxyglucose PET in large vessel vasculitis. Radiol Clin North Am 2007, 45:735-744.
Blockmans D PET in vasculitis. Ann N Y Acad Sci 2011, 1228:64-70.
Fuchs M, Briel M, Daikeler T, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012, 39:344-353.
Meller J, Strutz F, Siefker U, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003, 30:730-736.
Kobayashi Y, Ishii K, Oda K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med 2005, 46:917-922.
Peterson PL, Axford JS, Isenberg D Imaging in CNS lupus. Best Pract Res Clin Rheumatol 2005, 19:727-739.
Weiner SM, Otte A, Schumacher M, et al. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 2000, 59:377-385.
Serizawa I, Inubushi M, Kanegae K, et al. Lymphadenopathy due to amyloidosis secondary to Sjögren syndrome and systemic lupus erythematosus detected by F-18 FDG PET. Clin Nucl Med 2007, 32:881-882.
Seldin DW, Habib I, Soudry G Axillary lymph node visualization on F-18 FDG PET body scans in patients with rheumatoid arthritis. Clin Nucl Med 2007, 32:524-526.
Nowak M, Carrasquillo JA, Yarboro CH, et al. A pilot study of the use of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus. Arthritis Rheum 2004, 50:1233-1238.
Xiu Y, Yu JQ, Cheng E, et al. Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med 2005, 30:193-195.
Braun JJ, Kessler R, Constantinesco A, et al. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008, 35:1537-1543.
Yasuda S, Shohtsu A, Ide M, et al. F-18 FDG accumulation in inflamed joints. Clin Nucl Med 1996, 21:740.
Bakheet SMB, Powe J Fluorine-18-fluorodeoxyglucose uptake in rheumatoid-arthritis-associated lung disease in a patient with thyroid cancer. J Nucl Med 1998, 39:234-236.
Palmer WE, Rosenthal DI, Schoenberg OI, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995, 196:647-655.
Beckers C, Jeukens X, Ribbens C, et al. 18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging 2006, 33:275-280.
Matsui T, Nakata N, Nagai S, et al. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med 2009, 50:920-926.
Beckers C, Ribbens C, André B, et al. Assessment of disease activity in rheumatoid arthritis with 18F-FDG PET. J Nucl Med 2004, 45:956-964.
Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 2006, 31:386-390.
Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004, 22:3255-3260.
Pandit N, Gonen M, Krug L, et al. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003, 30:78-84.
Polisson RP, Schoenberg OI, Fischman A, et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:819-825.
Danfors T, Bergström M, Feltelius N, et al. Positron emission tomography with 11C-D-deprenyl in patients with rheumatoid arthritis. Scand J Rheumatol 1997, 26:43-48.
Yun M, Kim W, Adam L, et al. F-18 FDG uptake in a patient with psoriatic arthritis. Imaging correlation with patient symptoms. Clin Nucl Med 2001, 26:692-693.
Wendling D, Blagosklonov O, Streit G, et al. FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumor necrosis factor treatment. Ann Rheum Dis 2005, 64:1663-1665.
Wandler E, Kramer EL, Sherman O, et al. Diffuse FDG shoulder uptake on PET is associated with clinical findings of osteoarthritis. Am J Roentgenol 2005, 185:797-803.
Elzinga EH, van der Laken CJ, Comans EFI, et al. 2-deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol 2007, 9:357-360.
Nakamura H, Masuko K, Yudoh K, et al. Positron emission tomography with 18F-FDG in osteoarthritic knee. Osteoarthritis Cartilage 2007, 15:673-681.
ICRP Report 80. Ann ICRP 1999, 28:75.
Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005, 46:608-613.
